Screening for INF2 mutations, at least in exons 2 to 4, encoding the DID domain, should be strongly considered in patients with an AD familial history of FSGS, even before ACTN4 and TRPC6. The gene discussed is TRPC6; the disease is focal segmental glomerulosclerosis.